Aditxt enters asset purchase agreement to acquire MDNA's early cancer detection platform

Aditxt, Inc.

Pearsanta to acquire MDNA's early cancer detection IP for $1M cash + 50K Aditxt shares + warrants + Pearsanta preferred valued up to $25M.
Closing requires Aditxt/Pearsanta to raise at least $10M in debt or equity financing.
MDNA can terminate if Aditxt fails to pay $500K upfront working capital by December 31, 2023.
Pearsanta preferred shares designed to provide as-converted value of $25M; additional shares if shortfall.
Warrants for 50K Aditxt shares exercisable at closing price for 5 years.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.97

Aditxt, Inc. entered into Purchase Agreement with MDNA Life Sciences, Inc. (effective 2023-12-17).

Action: entry
Agreement: asset purchase
Counterparty: MDNA Life Sciences, Inc.
Effective: 2023-12-17

Exact text from the filing

On December 17, 2023, Aditxt, Inc., a Delaware corporation (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Pearsanta, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Pearsanta ”) and MDNA Life Sciences, Inc., a Delaware corporation (“ MDNA ”), pursuant to which Pearsanta will acquire certain intellectual property and other specified assets relating to MDNA’s early cancer detection platform.

View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-097705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.